ADMA Biologics
ADMA
10.14
-0.04
-0.39%
ADMA Biologics
US · ADMA
#2705 by market cap
Listed 1970
10.14
-0.04
-0.39%
Live - 5344 symbols - heartbeat 83s ago
· 2026-10-08 06:48
Pre-market
9.94
-1.98%
After-hours
10.14
0.00%
- Market cap
- 2.27B
- P/E (TTM)i
- 14.49
- P/Bi
- 5.57
- EPSi
- 0.60
- Div yieldi
- 0.00%
- 52W posi
- 22%
Reader sentiment
Are you bullish or bearish on ADMA?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Good
- Altman Z-Score is 11.51, above the 3.0 "safe zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year +19.63% YoY
Margins
- Gross margin
- 57.39%
- Operating margin
- 37.53%
- Net margin
- 28.80%
Key ratios & quality
- Enterprise valuei
- 2.26B
- Altman Z-Scorei
- 11.51
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 16.99M | 29.35M | 42.22M | 80.94M | 154.08M | 258.22M | 426.45M | 510.17M |
| Gross profit | -25.21M | -10.16M | -19.07M | 1.17M | 35.27M | 88.94M | 219.55M | 292.77M |
| Selling & admin expenses | 22.50M | 25.91M | 35.05M | 42.90M | 52.46M | 59.02M | 74.12M | 91.58M |
| Research & development | 3.93M | 2.34M | 5.91M | 3.65M | 3.61M | 3.30M | 1.81M | 4.76M |
| Operating profit | -60.29M | -41.42M | -64.91M | -58.37M | -39.37M | 21.63M | 138.98M | 191.44M |
| Pretax profit | -65.74M | -48.28M | -75.75M | -71.65M | -65.90M | -28.24M | 125.71M | 182.66M |
| Tax | -- | -- | -- | -- | 0 | 0 | -71.96M | 35.73M |
| Net profit | -65.74M | -48.28M | -75.75M | -71.65M | -65.90M | -28.24M | 197.67M | 146.93M |
| Basic EPS | -1 | -1 | -1 | -1 | 0 | 0 | 1 | 1 |
| Diluted EPS | -1.45 | -0.89 | -0.88 | -0.51 | -0.33 | -0.13 | 0.81 | 0.60 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 114.80M | 121.98M | 134.22M | 139.16M | 114.49M | 124.40M |
| Gross profit | 61.10M | 67.23M | 75.63M | 88.82M | 80.75M | 86.28M |
| Selling & admin expenses | 24.08M | 22.21M | 21.78M | 23.51M | 26.74M | 26.74M |
| Research & development | 826.00K | 1.03M | 1.53M | 1.38M | 2.60M | 6.01M |
| Operating profit | 34.88M | 42.80M | 51.01M | 62.75M | 50.29M | 52.45M |
| Pretax profit | 33.45M | 40.10M | 47.52M | 61.60M | 57.13M | 50.24M |
| Tax | 6.55M | 5.88M | 11.09M | 12.22M | 11.80M | 12.42M |
| Net profit | 26.90M | 34.22M | 36.43M | 49.38M | 45.33M | 37.82M |
| Basic EPS | 0 | 0 | 0 | 0 | 0 | 0 |
| Diluted EPS | 0.11 | 0.14 | 0.15 | 0.20 | 0.19 | 0.16 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 44.53M | 85.82M | 153.74M | 208.73M | 270.40M | 257.01M | 331.41M | 466.51M |
| Cash & ST investments | 22.75M | 26.75M | 55.92M | 51.09M | 86.52M | 51.35M | 103.15M | 87.63M |
| Inventory | 18.62M | 53.06M | 81.54M | 124.72M | 163.28M | 172.91M | 170.24M | 206.47M |
| Total assets | 88.88M | 127.09M | 207.67M | 276.25M | 348.46M | 329.18M | 488.68M | 624.24M |
| Total current liabilities | 9.63M | 14.03M | 19.95M | 30.38M | 39.27M | 49.81M | 55.54M | 69.54M |
| Short-term debt | 29.98K | 229.07K | 365.68K | 591.08K | 905.00K | 1.05M | 1.22M | 3.91M |
| Long-term debt | 44.08M | 83.20M | 92.97M | 94.87M | 142.83M | 130.59M | 72.34M | 69.33M |
| Total liabilities | 69,106,083.00 | 100,897,576.00 | 119,423,968.00 | 135,080,158.00 | 196,487,000.00 | 193,976,000.00 | 139,660,000.00 | 146,922,000.00 |
| Total equity | 19.77M | 26.19M | 88.25M | 141.17M | 151.97M | 135.21M | 349.02M | 477.32M |
| Retained earnings | -216.44M | -264.72M | -340.47M | -412.11M | -478.02M | -506.26M | -308.58M | -161.65M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 351.81M | 399.56M | 402.66M | 466.51M | 511.17M | 528.20M |
| Cash & ST investments | 71.63M | 90.29M | 61.39M | 87.63M | 138.15M | 136.02M |
| Inventory | 172.19M | 191.46M | 196.67M | 206.47M | 222.10M | 239.31M |
| Total assets | 510.57M | 558.38M | 568.69M | 624.24M | 665.18M | 684.21M |
| Total current liabilities | 53.50M | 74.94M | 56.49M | 69.54M | 73.54M | 75.76M |
| Short-term debt | 1.19M | 1.13M | 3.64M | 3.91M | 4.46M | 4.93M |
| Long-term debt | 72.53M | 73.40M | 70.08M | 69.33M | 193.58M | 192.84M |
| Total liabilities | 137,150,000.00 | 160,055,000.00 | 137,501,000.00 | 146,922,000.00 | 274,859,000.00 | 276,002,000.00 |
| Total equity | 373.42M | 398.33M | 431.19M | 477.32M | 390.33M | 408.21M |
| Retained earnings | -281.68M | -247.46M | -211.03M | -161.65M | -116.33M | -78.50M |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -62.68M | -76.19M | -102.00M | -112.37M | -59.51M | 8.80M | 118.67M | 50.40M |
| Depreciation & amortization | 3.45M | 3.26M | 3.94M | 5.50M | 7.11M | 8.33M | 8.05M | 8.10M |
| Free cash flow | -64.77M | -80.01M | -114.73M | -125.88M | -73.42M | 3.82M | 110.10M | 27.51M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 42.94M | 48.40M | 131.20M | 121.14M | 64.65M | 0 | 0 | -31.94M |
| Ending cash balance | 26.75M | 26.75M | 55.92M | 51.09M | 86.52M | 51.35M | 103.15M | 87.63M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | -19.68M | 21.14M | 13.29M | 35.64M | 58.25M | 29.54M |
| Depreciation & amortization | 1.97M | 2.06M | 2.02M | 2.05M | 1.84M | 1.78M |
| Free cash flow | -24.40M | 18.61M | -1.08M | 34.36M | 55.65M | 27.28M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 0 | 0 | -23.04M | -8.90M | -130.19M | -25.05M |
| Ending cash balance | 71.63M | 90.29M | 61.39M | 87.63M | 138.15M | 136.02M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | -218.77 | -210.08 | -132.38 | -62.46 | -44.96 | -19.67 | 81.65 | 35.56 |
| ROA %i | -66.78 | -44.71 | -45.25 | -29.61 | -21.10 | -8.33 | 48.34 | 26.40 |
| ROIC %i | -82.02 | -45.83 | -43.16 | -27.27 | -16.96 | -1.66 | 58.50 | 30.59 |
| 5-year avg ROE %i | -- | -- | -- | -173.53 | -133.73 | -93.91 | -35.56 | -1.98 |
| EBIT margin %i | -354.55 | -133.86 | -151.03 | -72.39 | -30.26 | -1.24 | 32.75 | 37.20 |
| FCF / sales %i | -- | -- | -- | -- | -- | 1.48 | 25.82 | 5.39 |
| Current ratioi | 4.63 | 6.12 | 7.71 | 6.87 | 6.89 | 5.16 | 5.97 | 6.71 |
| Quick ratioi | 2.51 | 2.15 | 3.47 | 2.62 | 2.60 | 1.58 | 2.76 | 3.54 |
| Debt / assetsi | 49.76 | 66.67 | 47.03 | 37.26 | 44.32 | 42.96 | 16.80 | 12.80 |
| LT debt / equityi | 223.54 | 322.61 | 110.26 | 72.48 | 101.03 | 103.82 | 23.18 | 15.92 |
| Interest coveragei | -10.90 | -4.37 | -5.32 | -4.49 | -2.42 | -0.13 | 10.02 | 26.69 |
| Revenue CAGR (3Y) %i | 33.26 | 40.15 | 22.87 | 68.28 | 73.80 | 82.88 | 74.01 | 49.05 |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | 78.45 | 71.23 | 63.17 | 35.56 | 43.30 | 41.90 |
| ROA %i | 48.01 | 44.70 | 43.67 | 26.40 | 28.13 | 27.19 |
| ROIC %i | 57.16 | 53.01 | 50.02 | 30.59 | 32.24 | 31.69 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | 33.28 | 32.73 | 33.60 | 37.20 | 41.89 | 43.98 |
| FCF / sales %i | 19.65 | 13.84 | 8.31 | 5.39 | 21.09 | 22.69 |
| Current ratioi | 6.58 | 5.33 | 7.13 | 6.71 | 6.95 | 6.97 |
| Quick ratioi | 3.20 | 2.67 | 3.52 | 3.54 | 3.73 | 3.62 |
| Debt / assetsi | 16.06 | 15.01 | 14.62 | 12.80 | 30.73 | 29.79 |
| LT debt / equityi | 21.64 | 20.76 | 18.43 | 15.92 | 51.23 | 48.73 |
| Interest coveragei | 12.60 | 15.23 | 19.63 | 26.69 | 29.52 | 25.53 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
✦ Quant Revenue Concentration how this is computed
Single-engine
- ADMA BioManufacturing is the largest reported line at 99.39% of revenue, across 3 reported segments.
- The next-largest line, Plasma Collection Centers, is a distant second at 0.58% - a sharp slowdown here would have little to offset it.
Revenue breakdown most recent period
Business
ADMA BioManufacturing99.39%
Plasma Collection Centers0.58%
Quote time 2026-10-08 06:48:57 · For reference only, not investment advice and not tailored to your situation.